AU2007243280A1 - Formulations containing pyridazine compounds for treating neuroinflammatory diseases - Google Patents

Formulations containing pyridazine compounds for treating neuroinflammatory diseases Download PDF

Info

Publication number
AU2007243280A1
AU2007243280A1 AU2007243280A AU2007243280A AU2007243280A1 AU 2007243280 A1 AU2007243280 A1 AU 2007243280A1 AU 2007243280 A AU2007243280 A AU 2007243280A AU 2007243280 A AU2007243280 A AU 2007243280A AU 2007243280 A1 AU2007243280 A1 AU 2007243280A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
formula
iii
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007243280A
Other languages
English (en)
Inventor
Wenhui Hu
Linda Van Eldik
Martin Watterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2007243280A1 publication Critical patent/AU2007243280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
AU2007243280A 2006-04-28 2007-04-27 Formulations containing pyridazine compounds for treating neuroinflammatory diseases Abandoned AU2007243280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79632806P 2006-04-28 2006-04-28
US60/796,328 2006-04-28
PCT/US2007/010248 WO2007127375A2 (en) 2006-04-28 2007-04-27 Formulations containing pyridazine compounds for treating neuroinflammatory diseases

Publications (1)

Publication Number Publication Date
AU2007243280A1 true AU2007243280A1 (en) 2007-11-08

Family

ID=38626233

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007243280A Abandoned AU2007243280A1 (en) 2006-04-28 2007-04-27 Formulations containing pyridazine compounds for treating neuroinflammatory diseases

Country Status (10)

Country Link
US (2) US20090325973A1 (enExample)
EP (1) EP2063894B1 (enExample)
JP (1) JP2009535344A (enExample)
CN (1) CN101754762A (enExample)
AU (1) AU2007243280A1 (enExample)
BR (1) BRPI0710938A2 (enExample)
CA (1) CA2650625A1 (enExample)
IL (1) IL194968A0 (enExample)
MX (1) MX2008013843A (enExample)
WO (1) WO2007127375A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
EP1812408B1 (en) 2004-11-02 2013-10-09 Northwestern University Pyridazine compounds, compositions and methods
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
BRPI0710938A2 (pt) 2006-04-28 2012-06-26 Univ Northwestern formulações contendo compostos de piridazina para o tratamento de doenças neuroinflamatórias
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20100227793A1 (en) * 2009-03-04 2010-09-09 Scott Thomas Brady Compositions and Methods for Treating Amyotrophic Lateral Sclerosis
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2011156901A2 (en) * 2010-06-17 2011-12-22 Waratah Pharmaceuticals Inc. Compounds, compositions and methods for treatment of multiple sclerosis
JP5916730B2 (ja) 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
ES2748656T3 (es) * 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
SG11202002941WA (en) * 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
EP4482495A4 (en) * 2022-02-23 2026-03-11 Immunochem Therapeutics Llc TREATMENT OF INTRACRANIAL HEMORRHAGE

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL92451C (enExample) * 1955-08-19
GB1345880A (en) * 1971-06-18 1974-02-06 Cepbepe Pyridazine derivatives
FR2510998B1 (fr) * 1981-08-07 1986-01-10 Sanofi Sa Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3217325A1 (de) 1982-05-08 1983-11-10 Hoechst Ag, 6230 Frankfurt 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
FR2601011B1 (fr) * 1986-07-03 1988-10-28 Sanofi Sa Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant
EP0351435B1 (en) * 1987-11-02 1993-08-04 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyridazine compounds and their medicinal uses
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US5484940A (en) * 1994-11-28 1996-01-16 Grant; Francine S. Substituted 3-indolyl-5-pyrazolone compounds
GB9707693D0 (en) 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US20030176437A1 (en) * 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US20040167226A1 (en) * 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
CA2532236C (en) * 2003-07-29 2011-08-23 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
TW200530246A (en) 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
HRP20070241T3 (hr) 2003-12-19 2007-07-31 Bristol-Myers Squibb Company Azabiciklički heterocikli kao modulatori kanabinoid receptora
US7220858B2 (en) * 2003-12-23 2007-05-22 Barbeau Pharma, Inc. Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines
MY145822A (en) * 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
EP1812408B1 (en) * 2004-11-02 2013-10-09 Northwestern University Pyridazine compounds, compositions and methods
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
WO2007127448A2 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
BRPI0710938A2 (pt) 2006-04-28 2012-06-26 Univ Northwestern formulações contendo compostos de piridazina para o tratamento de doenças neuroinflamatórias
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
AU2008223066A1 (en) 2007-03-02 2008-09-12 Northwestern University Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders

Also Published As

Publication number Publication date
MX2008013843A (es) 2008-11-10
IL194968A0 (en) 2009-08-03
EP2063894B1 (en) 2019-08-28
US20130072496A1 (en) 2013-03-21
CA2650625A1 (en) 2007-11-08
CN101754762A (zh) 2010-06-23
WO2007127375A2 (en) 2007-11-08
WO2007127375A3 (en) 2008-02-07
JP2009535344A (ja) 2009-10-01
US9408845B2 (en) 2016-08-09
EP2063894A2 (en) 2009-06-03
US20090325973A1 (en) 2009-12-31
BRPI0710938A2 (pt) 2012-06-26

Similar Documents

Publication Publication Date Title
US9408845B2 (en) Formulations containing pyridazine compounds
US8158627B2 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US9663493B2 (en) Pyridazine compounds, compositions and methods
US20100168120A1 (en) Salts of pyridazine compounds
WO2007130383A2 (en) Compositions and treatments using pyridazine compounds and secretases
US8063047B2 (en) Pyridazine compounds and methods
EP2131839A2 (en) Compositions comprising derivatives of 3-phenylpyridazine for treating seizure-related disorders
AU2012216322A1 (en) Pyridazine compounds, compositions and methods

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application